DZ2002

DZ2002 is a small molecule, reversible inhibitor of S-adenosyl-L-homocysteine hydrolase (SAHH), an enzyme critical for maintaining the methylation balance within cells. By blocking SAHH, DZ2002 causes an accumulation of S-adenosyl-L-homocysteine (SAH), which acts as a feedback inhibitor for various S-adenosyl-L-methionine (SAM)-dependent methyltransferases. This inhibition disrupts the methylation of proteins and DNA necessary for T-cell activation and the expression of inflammatory mediators. Developed by Ningbo Ziyuan Pharmaceutical Co., Ltd. in collaboration with the Shanghai Institute of Materia Medica, DZ2002 is being evaluated primarily as a topical treatment for plaque psoriasis and atopic dermatitis, where it aims to reduce skin inflammation and keratinocyte proliferation. It has also been explored in oral formulations for systemic autoimmune conditions such as systemic lupus erythematosus (SLE).